1. Search Result
Search Result
Results for "

acid secretion

" in MedChemExpress (MCE) Product Catalog:

658

Inhibitors & Agonists

5

Screening Libraries

3

Fluorescent Dye

18

Biochemical Assay Reagents

172

Peptides

2

Inhibitory Antibodies

106

Natural
Products

1

Recombinant Proteins

24

Isotope-Labeled Compounds

1

Click Chemistry

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117216B

    Neurokinin Receptor Neurological Disease
    L-703606 oxalate hydrate is a potent, selective antagonist of NK1 receptor. L-703606 can be used for study of gastric acid secretion .
    L-703606 oxalate hydrate
  • HY-P2416

    Rat Gastrin-17

    Cholecystokinin Receptor Endocrinology
    Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently .
    Gastrin I, rat
  • HY-136301

    Others Inflammation/Immunology
    Acid secretion-IN-1 is a polycyclic compound extracted from patent WO2018024188A1, Compound Example 17.4. Acid secretion-IN-1 is synthesized and used in the IDO inhibitor synthetic experiment .
    Acid secretion-IN-1
  • HY-117216

    Neurokinin Receptor Neurological Disease
    L-703606 is a potent, selective antagonist of NK1 receptor. L-703606 can be used for study of gastric acid secretion .
    L-703606
  • HY-117216A

    Neurokinin Receptor Neurological Disease
    L-703606 oxalate is a potent, selective antagonist of NK1 receptor. L-703606 can be used for study of gastric acid secretion .
    L-703606 oxalate
  • HY-119991

    Proton Pump Bacterial Metabolic Disease
    AHR-9294 is an inhibitor of the H + pump enzyme and H, K-ATPase. AHR-9294 inhibits acid secretion in vivo .
    AHR-9294
  • HY-19580

    CM 57755A

    Histamine Receptor Endocrinology
    Ramisotidine is a histamine H2 receptor antagonist that can inhibit gastric acid secretion stimulated by pentagastrin .
    Ramixotidine
  • HY-130522

    6β-PGI1

    Others Others
    6β-Prostaglandin I1 (6β-PGI1) is an analog of prostaglandin I2 (PGI2) that is resistant to hydrolysis in aqueous solutions. 6β-Prostaglandin I1 can reduce gastric acid secretion with an ID50 (dose causing 50% inhibition) of approximately 3.0 μg/kg/min (intravenous injection) .
    6β-Prostaglandin I1
  • HY-116777A

    SKF 92676 hydrochloride

    Histamine Receptor Others
    Impromidine hydrochloride is a potent agonist for histamine H2 receptor. Impromidine hydrochloride induces gastric mucosal blood flow and acid secretion .
    Impromidine hydrochloride
  • HY-17623R

    Proton Pump Metabolic Disease
    Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
    Tegoprazan (Standard)
  • HY-116777

    SKF 92676

    Histamine Receptor Others
    Impromidine (SKF 92676) is a potent agonist for histamine H2 receptor. Impromidine induces gastric mucosal blood flow and acid secretion .
    Impromidine
  • HY-W018512
    7-Ketolithocholic acid
    2 Publications Verification

    3α-Hydroxy-7-oxo-5β-cholanic acid

    Endogenous Metabolite Metabolic Disease
    7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .
    7-Ketolithocholic acid
  • HY-103355
    YM022
    1 Publications Verification

    CCR Metabolic Disease
    YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
    YM022
  • HY-17623D

    CJ-12420 Benzoate; RQ-00000004 Benzoate

    Proton Pump Metabolic Disease
    Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
    Tegoprazan Benzoate
  • HY-121450

    Loxtidine; AH-234844

    Histamine Receptor Cancer
    Lavoltidine (Loxtidine) is an an orally active, irreversible and highly potent histamine H2-receptor antagonist. Lavoltidine strongly inhibits gastric acid secretion and also induces hypergastrinemia .
    Lavoltidine
  • HY-114360
    Taurohyodeoxycholic acid
    1 Publications Verification

    Endogenous Metabolite Metabolic Disease
    Taurohyodeoxycholic acid is the tauroconjugated form of Hyodeoxycholic acid (HDCA, a dihydroxylated natural bile acid). Taurohyodeoxycholic acid induces a biliary phospholipid secretion and suggests a hepatoprotective potential. Taurohyodeoxycholic acid also can promote gallstone dissolution .
    Taurohyodeoxycholic acid
  • HY-B1557
    Betazole
    1 Publications Verification

    Ametazole

    Histamine Receptor Metabolic Disease
    Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
    Betazole
  • HY-B1557A

    Ametazole dihydrochloride

    Histamine Receptor Metabolic Disease
    Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .
    Betazole dihydrochloride
  • HY-B1557R

    Histamine Receptor Metabolic Disease
    Betazole (Standard) is the analytical standard of Betazole. This product is intended for research and analytical applications. Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
    Betazole (Standard)
  • HY-160979

    DA-5047

    Histamine Receptor Others Endocrinology
    Bisfentidine is an H2 receptor antagonist, Bisfentidine can block the H2 receptor on the cells of the stomach wall, and reduce the secretion of stomach acid. Bisfentidine binds to cytochrome P-450 in liver microsomes and affects drug metabolism. Bisfentidine can be used in the study of metabolic processes of drugs, lipid peroxidation processes and peptic ulcers diseases .
    Bisfentidine
  • HY-17623
    Tegoprazan
    2 Publications Verification

    CJ-12420; RQ-00000004

    Proton Pump Potassium Channel Na+/K+ ATPase Inflammation/Immunology
    Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan
  • HY-14850

    Netazepide; YF 476; YM-220

    Cholecystokinin Receptor Metabolic Disease Endocrinology
    Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively .
    Sograzepide
  • HY-129357

    Cholecystokinin Receptor Metabolic Disease
    CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC50 of 1.82 μM .
    CCK-B Receptor Antagonist 2
  • HY-158320

    Bacterial Infection
    T3SS-IN-5 (Compound F9) is a specific inhibitor of the type III secretion system (T3SS). T3SS-IN-5 reduces bacterial pathogenicity without affecting bacterial viability by inhibiting the expression of genes associated with T3SS .
    T3SS-IN-5
  • HY-P1139

    PCFWKTCK

    GHSR Metabolic Disease
    Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .
    Cortistatin-8
  • HY-N7031

    (±)​-Peganine

    Proton Pump Inflammation/Immunology
    (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H +-K +-ATPase activity?in vitro?with an IC50 of 73.47?μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and?cytoprotective?effect .
    (±)​-​Vasicine
  • HY-N7031R

    Proton Pump Inflammation/Immunology
    (±)?-Vasicine (Standard) is the analytical standard of (±)?-Vasicine. This product is intended for research and analytical applications. (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H+-K+-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .
    (±)​-​Vasicine (Standard)
  • HY-A0234

    Prostenoglycine; TTPG; Tiase

    Others Endocrinology
    Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin
  • HY-P1202
    CYN 154806
    1 Publications Verification

    Somatostatin Receptor Endocrinology
    CYN 154806, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .
    CYN 154806
  • HY-P1202A
    CYN 154806 TFA
    1 Publications Verification

    Somatostatin Receptor Endocrinology
    CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .
    CYN 154806 TFA
  • HY-109079A

    DWP14012 hydrochloride; Fexuprazan hydrochloride

    Proton Pump Metabolic Disease
    Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan hydrochloride
  • HY-109079

    DWP14012; Fexuprazan

    Proton Pump Metabolic Disease
    Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan
  • HY-17421

    TU-199

    Proton Pump Infection Inflammation/Immunology
    Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H +/K +-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .
    Tenatoprazole
  • HY-13100

    Proton Pump Metabolic Disease
    PF 03716556 is a potent, selective, competitive and reversible acid pump (H +,K +-ATPase) antagonist with pIC50s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H +,K +-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research .
    PF 03716556
  • HY-A0234R

    Others Endocrinology
    Stepronin (Standard) is the analytical standard of Stepronin. This product is intended for research and analytical applications. Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin (Standard)
  • HY-19010A

    SKF 94482 hydrochloride

    Histamine Receptor Neurological Disease
    BMY-25368 hydrochloride is a histamine H2 receptor antagonist that acts as a gastric acid secretion inhibitor. BMY-25368 hydrochloride competitively antagonizes gastric secretion stimulated by histamine and also antagonizes gastric secretion stimulated by Pentagastrin (HY-A0261), Bethanechol (HY-B0406), and food .
    BMY-25368 hydrochloride
  • HY-19010

    SKF 94482

    Histamine Receptor Neurological Disease
    BMY-25368 (SKF 94482) is a histamine H2 receptor antagonist that acts as a gastric acid secretion inhibitor. BMY-25368 competitively antagonizes gastric secretion stimulated by histamine and also antagonizes gastric secretion stimulated by Pentagastrin (HY-A0261), Bethanechol (HY-B0406), and food .
    BMY-25368
  • HY-B1223
    Anethole trithione
    2 Publications Verification

    mAChR Neurological Disease Cancer
    Anethole trithione, a sulfur heterocyclic choleretic, is a bile secretion-stimulating agent. Anethole trithione enhances salivary secretion and increases mAChRs, and can be used for dry mouth research .
    Anethole trithione
  • HY-131637

    Others Metabolic Disease
    Desacetyl bisacodyl is the active metabolite of the laxative bisacodyl. Desacetyl bisacodyl induces epithelial Cl(-) secretion in rat colon and rectum. Desacetyl bisacodyl evokes several effects at the colon or rectum, including increased mucus and chloride secretion .
    Desacetyl bisacodyl
  • HY-N12653

    (-)-Exserohilone

    Reactive Oxygen Species Metabolic Disease
    Exserohilone ((-)-Exserohilone) is a thiodiketopiperazine derivative that exhibits the inhibition of TNF-α-induced ROS generation and MMP-1 secretion. Exserohilone increases the procollagen type I α1 secretion in human dermal fibroblasts .
    Exserohilone
  • HY-P2537

    HIV Apelin Receptor (APJ) Others
    Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect .
    Apelin-12
  • HY-102052

    Potassium Channel Inflammation/Immunology
    DCEBIO, a derivative of 1-EBIO, is an extremely potent activator of Cl - secretion in T84 colonic cells . DCEBIO stimulates Cl - secretion via the activation of hIK1 K + channels and the activation of an apical membrane Cl - conductance .
    DCEBIO
  • HY-106550

    RS 84135

    Others Endocrinology
    Enprostil (RS 84135) is a prostaglandin E2 derivative. Enprostil can inhibit amogastrin-stimulated gastric acid secretion, as well as reducing the secretion of pepsin. Enprostil can also serve as an antiulcer agent, used for research of duodenal or gastric ulcers .
    Enprostil
  • HY-P0150

    GCGR Neurological Disease
    Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
    Glucagon (19-29), human
  • HY-P0276
    GIP, human
    1 Publications Verification

    Gastric Inhibitory Peptide (GIP), human

    Insulin Receptor Metabolic Disease
    GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human
  • HY-100284

    Others Inflammation/Immunology
    Thiazolidinone-Derivatives-1 is an antiulcer agent which inhibits the secretion of gastric acid.
    Thiazolidinone-Derivatives-1
  • HY-P5641

    Bacterial Infection
    Pleurocidin is an antibacterial peptide derived from skin secretions of Winter Flounder .
    Pleurocidin
  • HY-N12058

    Others Others
    (Z)-9-Nonadecene is the anal secretion of a species of thrips .
    (Z)-9-Nonadecene
  • HY-P1174

    GnRH Receptor Endocrinology
    GnRH Associated Peptide (GAP) (1-13), human is an amino acid peptide fragment derived from GnRH. GAP can increase the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in rat anterior pituitary cells. GAP also inhibit the secretion of prolactin .
    GnRH Associated Peptide (GAP) (1-13), human
  • HY-P0276A
    GIP, human TFA
    1 Publications Verification

    Gastric Inhibitory Peptide (GIP), human TFA

    Insulin Receptor Metabolic Disease
    GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: